文献速递银屑病与炎症性皮肤病

银屑病生物标志物及临床应答轨迹对UVB光疗清除与缓解期的预测作用

The use of psoriasis biomarkers, including trajectory of clinical response, to predict clearance and remission duration to UVB phototherapy.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2021-08-03

该前瞻性队列研究纳入100例接受窄谱UVB治疗的银屑病患者,随访18个月,评估临床及血清生物标志物与缓解期和光疗结束时清除的关系。结果显示达到PASI90者中位复发时间6个月,未达PASI90者4个月;第3周达到PASI30与疗程结束时PASI90显著相关。BMI升高和吸烟预测光疗反应较差。

要点

  • 达到PASI90者中位复发时间6个月,未达PASI90者4个月,PASI100未延长缓解。
  • 第2-3周PASI清除轨迹可预测最终清除,如第3周PASI30与末期PASI90显著相关。
  • BMI升高和吸烟预测光疗反应较差,CRP和维生素D与清除或缓解无关。

核心结论

  • BMI升高和吸烟预测光疗反应较差。
  • UVB治疗前2-3周的PASI清除轨迹可预测银屑病最终清除。
  • 达到PASI90者中位复发时间6个月,未达PASI90者4个月,PASI100未延长缓解。

研究设计与样本

  • 前瞻性队列研究,纳入100例常规接受窄谱UVB治疗的银屑病患者,随访18个月。
  • 测量选定的临床和生化生物标志物,包括每周PASI评分。

主要发现

  • 光疗结束时中位最终PASI(n=96)为1.0(IQR 0.5, 1.6),78例(81%)达到PASI75,39例(41%)达到PASI90。
  • PASI90应答改善与较低BMI、较高基线PASI、不吸烟状态和较低累积NbUVB显著相关。
  • 血清CRP和维生素D水平与清除或缓解期无关。
  • 第3周达到PASI30与疗程结束时PASI90显著相关[36/77(51%)vs. 2/24(8%),P < 0.001]。

关键数值与推荐

  • 达到PASI90者中位复发时间6个月(95% CI 5-18),未达PASI90者4个月(95% CI 3-9)。

临床怎么用

  • 早期治疗反应(第2-3周)可用于预测最终清除,帮助告知患者治疗预期。
  • 根据早期轨迹可考虑调整治疗或换用替代疗法。
  • BMI升高和吸烟者光疗反应可能较差,应纳入临床评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Remission duration and treatment response following phototherapy for psoriasis are highly variable and factors influencing these are poorly understood. OBJECTIVES: Our primary outcome was to investigate whether selected clinical/serum biomarkers were associated with remission duration, and secondly with psoriasis clearance at the end of phototherapy. In addition, we looked at whether early trajectory of UVB clearance was associated with final clearance outcome. METHODS: We performed a prospective cohort study of 100 psoriasis patients, routinely prescribed Narrowband UVB and measured selected clinical and biochemical biomarkers, including weekly PASI (psoriasis area and severity index) scores. Patients were followed up for 18 months. RESULTS: The median time to relapse was 6 months (95% CI 5-18) if PASI90 was achieved, and 4 months (95% CI 3-9) if less than PASI90 was achieved. Achieving PASI100 did not result in prolonged remission. On UVB completion, the median final PASI (n = 96) was 1.0 (IQR 0.5, 1.6) with 78 (81%) achieving PASI75 and 39 (41%) achieving PASI90. Improved PASI90 response was significantly associated with lower BMI, higher baseline PASI, non-smoking status and lower cumulative NbUVB. Serum levels of C-reactive protein (CRP) and vitamin D were not associated with clearance or remission duration. Early treatment response from weeks 2-3 was predictive of final outcome. For example, achieving PASI30 at week 3 was significantly associated with PASI90 at the end of the course [36/77 (51%) vs. 2/24 (8%), P < 0.001]. CONCLUSIONS: Raised BMI and positive smoking status predicted poorer phototherapy response. For the first time, we have shown that PASI clearance trajectory over the first 2-3 weeks of UVB, can predict psoriasis clearance. This is an important new step towards developing psoriasis personalized prescribing, which can now be formally tested in clinical trials. These simple clinical measures can be used to inform patient treatment expectations; allowing treatment modifications and/or switching to alternative therapies.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Watson N, Wilson N, Shmarov F, et al. The use of psoriasis biomarkers, including trajectory of clinical response, to predict clearance and remission duration to UVB phototherapy. J Eur Acad Dermatol Venereol. 2021. PMID: 34255884. doi:10.1111/jdv.17519

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。